TCGA-OL-A66O-01A-11R-A31O-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 18
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.420
- DNA_REPAIR+0.360
- ESTROGEN_RESPONSE_LATE+0.360
- OXIDATIVE_PHOSPHORYLATION+0.340
- ESTROGEN_RESPONSE_EARLY+0.330
- KRAS_SIGNALING_DN+0.230
- MYC_TARGETS_V1+0.200
- BILE_ACID_METABOLISM+0.190
- E2F_TARGETS+0.190
- MYOGENESIS+0.160
Top 10 suppressed
- PROTEIN_SECRETION-0.470
- INFLAMMATORY_RESPONSE-0.450
- HEDGEHOG_SIGNALING-0.430
- IL6_JAK_STAT3_SIGNALING-0.430
- KRAS_SIGNALING_UP-0.430
- ALLOGRAFT_REJECTION-0.410
- UV_RESPONSE_DN-0.400
- INTERFERON_GAMMA_RESPONSE-0.380
- MITOTIC_SPINDLE-0.360
- COMPLEMENT-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-B6-A0IE-01A-11R-A034-07 | — | B | 0.870 |
| 2 | TCGA-E2-A576-01A-11R-A31O-07 | — | B | 0.865 |
| 3 | TCGA-JL-A3YX-01A-11R-A22U-07 | — | B | 0.854 |
| 4 | TCGA-E9-A54Y-01A-11R-A466-07 | — | B | 0.853 |
| 5 | TCGA-CQ-A4C9-01A-11R-A24Z-07 | — | — | 0.842 |
| 6 | SJEPD001539_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.841 |
| 7 | TCGA-AC-A62V-01A-11R-A31O-07 | — | B | 0.833 |
| 8 | 85d43afd-9aac-48ca-a9c4-00357b7207e1 | — | — | 0.831 |
| 9 | TCGA-LL-A5YM-01A-11R-A28M-07 | — | B | 0.823 |
| 10 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.420 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.360 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.340 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.120 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |
| COAGULATION | 0.030 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| UV_RESPONSE_UP | 0.030 | Idelalisib | — uncovered |